These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
32. Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed? Yeboah J Atherosclerosis; 2013 Feb; 226(2):335-6. PubMed ID: 23153621 [No Abstract] [Full Text] [Related]
33. Statins for patients with type 2 diabetes. Auer J; Berent R; Weber T; Eber B Lancet; 2004 Nov 27-Dec 3; 364(9449):1933-4. PubMed ID: 15566997 [No Abstract] [Full Text] [Related]
34. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Bellanger N; Julia Z; Villard EF; El Khoury P; Duchene E; Chapman MJ; Fournier N; Le Goff W; Guerin M Atherosclerosis; 2012 Mar; 221(1):160-8. PubMed ID: 22265126 [TBL] [Abstract][Full Text] [Related]
35. [Effects of statins on coronary artery disease. Review of the recent publications]. Bednarz B Przegl Lek; 2003; 60(1):27-9. PubMed ID: 12884643 [TBL] [Abstract][Full Text] [Related]
36. Profound regression of coronary atherosclerosis with statins. Abdallah MH; Karrowni W; Dakik HA Can J Cardiol; 2006 Jun; 22(8):709. PubMed ID: 16802002 [No Abstract] [Full Text] [Related]
37. [Aggressive therapy and combination therapy in severe hyperlipidemia]. Kostner KM Wien Med Wochenschr; 1999; 149(5-6):146-8. PubMed ID: 10408007 [TBL] [Abstract][Full Text] [Related]
38. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Catalano G; Julia Z; Frisdal E; Vedie B; Fournier N; Le Goff W; Chapman MJ; Guerin M Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):268-75. PubMed ID: 19038848 [TBL] [Abstract][Full Text] [Related]
39. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Kakuda H; Matoba M; Nakatoh H; Nagao S; Takekoshi N Scand J Clin Lab Invest; 2014 Jun; 74(4):285-95. PubMed ID: 24564634 [TBL] [Abstract][Full Text] [Related]
40. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Uzun M; Yiğiner O; Kirilmaz A Turk Kardiyol Dern Ars; 2009 Jul; 37(5):364; author reply 365. PubMed ID: 19875919 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]